Skip to Content
Merck
All Photos(1)

Documents

C0246

Sigma-Aldrich

Cabergoline

≥98% (HPLC)

Synonym(s):

1-Ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′β-carbonyl)urea, 1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea, Cabaser, Dostinex, FCE-21336

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C26H37N5O2
CAS Number:
81409-90-7
Molecular Weight:
451.60
MDL number:
MFCD00867887
UNSPSC Code:
12352200
PubChem Substance ID:
329774771
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

optical activity

[α]/D −63 to −74°, c = 0.5 in dichloromethane

solubility

DMSO: ≥10 mg/mL

originator

Johnson & Johnson

storage temp.

2-8°C

SMILES string

CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1

InChI

1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1

InChI key

KORNTPPJEAJQIU-KJXAQDMKSA-N

Gene Information

human ... DRD2(1813)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H362

Hazard Classifications

Acute Tox. 4 Oral - Lact.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Samuel Santos-Ribeiro et al.
Journal of assisted reproduction and genetics, 32(7), 1063-1068 (2015-05-20)
We report on the results of the whole-genome analysis performed in a patient who developed severe ovarian hyperstimulation syndrome (OHSS) following gonadotropin-releasing hormone (GnRH) agonist triggering in a "freeze-all" protocol. A 30-year-old patient with polycystic ovary syndrome who developed severe
Rivka Inzelberg et al.
Drugs & aging, 20(11), 847-855 (2003-09-11)
Dopamine agonists have been widely used as add-on to levodopa in the treatment of Parkinson's disease with motor fluctuations. However, the use of dopamine agonists in early Parkinson's disease and levodopa-naive patients is controversial. Although dopamine agonists have been compared
Paolo Del Dotto et al.
Clinical pharmacokinetics, 42(7), 633-645 (2003-07-08)
Cabergoline is a synthetic ergoline dopamine agonist with a high affinity for D(2) receptors indicated for use in both early and advanced Parkinson's disease and in hyperprolactinaemic disorders. Following oral administration, peak plasma concentrations of cabergoline are reached within 2-3
Vania dos Santos Nunes et al.
Pituitary, 14(3), 259-265 (2011-01-12)
Cabergoline and bromocriptine are the most used drugs in the treatment of hyperprolactinemia, they are able to normalize the prolactin levels, restore gonadal function and promote tumor reduction in the majority of patients. We undertake a systematic review and meta-analysis
Renata S Auriemma et al.
European journal of endocrinology, 169(3), 359-366 (2013-07-05)
Cabergoline (CAB) has been found to be associated with increased risk of cardiac valve regurgitation in Parkinson's disease, whereas several retrospective analyses failed to detect a similar relation in hyperprolactinemic patients. The current study aimed at investigating cardiac valve disease
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service